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Abstract
Aims/hypothesis Liver X receptors (LXRs) play important
roles in lipid and carbohydrate metabolism. The purpose of the
present study was to evaluate effects of the endogenous LXR
agonist 22-R-hydroxycholesterol (22-R-HC) and its stereo-
isomer 22-S-hydroxycholesterol (22-S-HC), in comparison
with the synthetic agonist T0901317 on lipid and glucose
metabolism in human skeletal muscle cells (myotubes).
Methods Myotubes established from lean and obese control
volunteers and from obese type 2 diabetic volunteers were
treated with LXR ligands for 4 days. Lipid and glucose
metabolisms were studied with labelled precursors, and gene
expression was analysed using real-time PCR.
Results Treatment with T0901317 increased lipogenesis (de
novo lipid synthesis) and lipid accumulation in myotubes,
this increase being more pronounced in myotubes from type
2 diabetic volunteers than from lean volunteers. Furthermore,
22-S-HC efficiently counteracted the T0901317-induced
enhancement of lipid formation. Moreover, synthesis of
diacylglycerol, cholesteryl ester and free cholesterol from
acetate was reduced below baseline by 22-S-HC, whereas
glucose uptake and oxidation were increased. Both 22-S-HC
and 22-R-HC, in contrast to T0901317, decreased the
expression of genes involved in cholesterol synthesis,
whereas only 22-R-HC, like T0901317, increased the
expression of the gene encoding the reverse cholesterol
transporter ATP-binding cassette subfamily A1 (ABCA1).
Conclusions/interpretation T0901317-induced lipogenesis
and lipid formation was more pronounced in myotubes
from type 2 diabetic patients than from lean individuals.
22-S-HC counteracted these effects and reduced de novo
lipogenesis below baseline, while glucose uptake and
oxidation were increased.
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Abbreviations
ChREBP carbohydrate responsive element-binding
protein
FASN fatty acid synthase
HMGC hydroxymethylglutaryl-coenzyme A
LXR liver X receptor
22-R-HC 22-R-hydroxycholesterol
22-S-HC 22-S-hydroxycholesterol
SREBP sterol regulatory element-binding protein
SCD1 stearoyl-coenzyme A desaturase 1
Introduction
Type 2 diabetes is an increasing health problem in Western
society and is associated with obesity, insulin resistance and
high plasma levels of glucose, triacylglycerol and choles-
terols. Liver X receptors (LXRs) are in focus because of
Diabetologia (2007) 50:2171–2180
DOI 10.1007/s00125-007-0760-7
DO00760; No of Pages
E. T. Kase :G. H. Thoresen :A. C. Rustan (*)
Department of Pharmaceutical Biosciences, School of Pharmacy,
University of Oslo, Blindern,
P.O. Box 1068, Oslo 0316, Norway
e-mail: arild.rustan@farmasi.uio.no
S. Westerlund
Department of Molecular Pharmacology,
AstraZeneca Research and Development,
Molndal, Sweden
K. Højlund :M. Gaster
KMEB, Department of Endocrinology,
Odense University Hospital,
Odense, Denmark
their role in cholesterol, lipid and carbohydrate metabolism
[1–4]. Cholesterol metabolites are endogenous ligands for
LXR [5–7] and might therefore play an essential role in the
pathophysiology of type 2 diabetes and obesity.
LXRs form heterodimers with the 9-cis retinoic acid
receptor and bind to DNA in this form [8–10]. Two LXR
genes have been identified, LXRα and LXRβ (also known
as NR1H3 and NR1H2, respectively), which encode highly
preserved isoforms [11–13]. The LXRβ isoform is ubiqui-
tously expressed [8], whereas LXRα is mainly restricted to
tissues known to play an important role in lipid metabolism,
such as liver, adipose tissue, macrophages, kidney, skeletal
muscle and small intestine [10, 14, 15]. Further, human
skeletal muscle cells have higher levels of LXRβ than
LXRα [16].
LXRs have profound effects on hepatic lipid metabolism.
These effects are mediated in part through the transcriptional
regulation of the gene for sterol regulatory element-binding
protein-1c (SREBP-1c), the master transcriptional regulator of
fatty acid and triacylglycerol synthesis [17, 18]. Also, the
gene encoding carbohydrate responsive element-binding
protein (ChREBP, also known as MLXIPL), a glucose-
sensitive transcription factor that promotes hepatic conversion
of excess carbohydrate to lipid, has recently been identified as
an LXR target gene [19]. In addition to SREBP-1c and
ChREBP, the genes for other lipogenic enzymes, such as fatty
acid synthase (FASN), have been reported as direct LXR
targets [20]. LXRs are also well known sensors of cholesterol
metabolism and control reverse cholesterol transport through
regulation of ABC transporters [3, 21–23]. When fed a high-
fat, high-cholesterol diet, LXR-null mice are resistant to
obesity and demonstrate better glucose tolerance. Interesting-
ly, on the same diet without cholesterol, LXR-null mice
gained weight like their wild-type controls, possibly suggest-
ing that LXR regulation of lipid metabolism is integrated
through their role in cholesterol homeostasis [24].
The regulation of LXRα expression in adipocytes is well
defined [25–28], but its role in adipocyte lipid metabolism
remains unclear, as studies have reported contradictory
results. Synthetic LXR agonists (T0901317 or GW3965)
were shown to have no effects on triacylglycerol accumu-
lation in adipocytes [27], while Juvet et al. [26] reported
that these compounds were able to increase the size of lipid
droplets in 3T3-L1 cells without affecting the expression of
Srebp-1 (also known as Srebf1) or the gene for the fatty
acid transporter (Fat, also known as Cd36). Recently, Seo
et al. [28] showed that T0901317 increased lipid storage in
3T3-L1 cells and enhanced the expression of Srebp-1c,
Fasn and the genes for adipocyte fatty acid binding protein
2 (Ap2, also known as Fabp4) and peroxisome proliferator-
activated receptor γ (Pparg).
Literature describing the role of LXRs on de novo lipid
formation in human skeletal muscle is scarce. Cozzone et al.
[29] reported on the basis of gene expression data that LXR
agonists may promote increased utilisation of lipids and
glucose in muscle cells without affecting insulin action. We
have recently reported that: (1) an LXR agonist (T0901317)
activates lipogenesis (de novo synthesis of lipids) and lipid
accumulation in human myotubes; (2) the endogenous LXR
ligand, 22-R-hydroxycholesterol (22-R-HC) affects gene
expression differently than the synthetic stereoisomer 22-S-
hydroxycholesterol (22-S-HC); and (3) 22-S-HC reduces
synthesis of lipids and represses certain genes involved in
lipogenesis and lipid handling by acting like an LXR
antagonist [30, 31]. In addition, we have previously shown,
using radiolabelled energy substrates, that chronic hyper-
glycaemia promotes lipogenesis, increases triacylglycerol
formation and reduces glucose uptake in human skeletal
muscle cells [32].
To date, several forms of treatments (lifestyle and drugs)
are available for type 2 diabetes, but none efficiently
control or cure the disease. The physiological roles of LXR
suggest that it may be an interesting target for drug
treatment of type 2 diabetes. Indeed, in a recent study we
showed that activation of the LXR pathway in human
skeletal muscle may be involved in increased accumulation
of intramyotubular lipids in type 2 diabetes [33]. The
purpose of the present study was to test whether the newly
identified LXR antagonist, 22-S-HC [30], could have
beneficial effects on de novo fatty acid synthesis and lipid
metabolism, as well as glucose metabolism in myotubes
established from lean, obese and obese type 2 diabetic
individuals.
Methods
Materials DMEM-Glutamax, FCS, Ultroser G, penicillin–
streptomycin–amphotericin B and trypsin–EDTA were
obtained from Life Technology (Paisley, UK). Skeletal
Muscle Growth Medium Bullet Kit was obtained from
Clonetics (BioWittaker, Verviers, Belgium). [1-14C]Palmitic
acid (2.0 GBq/mmol), 2-deoxy-D-[3H]glucose (222 GBq/
mmol) and D-[U-14C]glucose (4.5 GBq/mmol) were pur-
chased from Dupont NEN Life Science Products (Boston,
MA, USA). [1-14C]acetic acid (2.0 GBq/mmol) and
D-[1-14C]glucose (2.0 GBq/mmol) were purchased from
American Radiolabeled Chemicals (St Louis, MO, USA).
Palmitic acid, BSA (essentially fatty acid-free), cytochala-
sin B and extracellular matrix gel were purchased from
Sigma Chemicals (St Louis, MO, USA). Insulin Actrapid
was from Novo Nordisk (Bagsvaerd, Denmark). RNeasy
Mini kit and RNase-free DNase were purchased from
Qiagen Sciences (Oslo, Norway). Primers (directed against
36B4, the gene for glyceraldehyde-3-phosphate dehydroge-
nase [GAPDH], GLUT1 [also known as SLC2A1], GLUT4
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[also known as SLC2A4] and ChREBP) were purchased
from Invitrogen (Oslo, Norway). High capacity cDNA
archive kit, SYBR Green, TaqMan reverse-transcription
reagents kit, TaqMan Universal PCR Master Mix and micro
fluidic cards were purchased from Applied Biosystems
(Warrington, UK). Protein assay kit was purchased from
BioRad (Copenhagen, Denmark). T0901317 was obtained
from Cayman Chemicals (Ann Arbor, MI, USA). 22-R-HC
and 22-S-HC were purchased from Sigma. A Cholesterol
RTU Kit was provided by bioMéreiux (Marcy l’Etoile,
France) and the cytotoxicity detection kit (Cytotoxicty plus)
was purchased from Roche (Mannheim, Germany). All
other chemicals used were of standard commercial high-
purity quality.
Human participants A cell-bank of satellite cells was
established from muscle biopsy samples of the M. vastus
lateralis of seven lean and seven obese control volunteers
and seven obese type 2 diabetic volunteers, as previously
described [33]. Groups were matched with respect to age,
but differed by BMI, fasting plasma glucose concentrations,
fasting serum insulin levels, hyperinsulinaemic–euglycae-
mic clamp results and HbA1c (Table 1). Muscle biopsies
were obtained in the fasted state by needle biopsy under
local anaesthesia. All participants gave written informed
consent; the local ethics committee of Funen and Vejle
County (Denmark) approved the study.
Cell culture Cell cultures were established from satellite
cells [34]. Briefly, muscle tissue was dissected in Ham’s F-10
media at 4°C and dissociated by three successive treatments
with 0.05% trypsin/EDTA, after which satellite cells were
resuspended in Skeletal Muscle Growth Medium (2% FCS)
without insulin. The cells were grown on wells coated with
extracellular matrix gel. At about 80% confluence, fusion of
myoblasts into multinucleated myotubes was achieved by
growth for 8 days in DMEM with 2% FCS, physiological
concentrations of insulin (25 pmol/l) and glucose (5.5 mmol/l).
On day 4, myotubes were exposed to either vehicle (0.1%
DMSO), 1 μmol/l T0901317, 1 μmol/l T0901317+10 μmol/
l 22-S-HC, 10 μmol/l 22-S-HC or 10 μmol/l 22-R-HC for
4 days.Myotubes were rinsed twice and incubated for 4 h either
with labelled palmitic acid, acetate or glucose as described
below. Protein content of each sample was determined as
described previously [35]. Corresponding RNA extractions
were also obtained.
Cytotoxicity A cytotoxicity detection kit (Roche) was used
according to the suppliers protocol to measure total and
extra-cellular lactate dehydrogenase, which is a marker for
cellular lysis.
Lipid distribution from labelled acetate To study lipid
distribution from labelled acetate, myotubes were exposed to
DMEM supplemented with 0.24 mmol/l BSA, 1.0 mmol/l
L-carnitine, 25 pmol/l insulin, 10 mmol/l HEPES, [1-14C]
acetate (74 kBq/ml, 0.1 mmol/l) and 25 pmol/l insulin for
4 h. Myotubes were placed on ice, washed with PBS (1 ml),
harvested into a tube with two additions of 125 μl distilled
water and frozen at −20°C. Cells were later assayed for
protein [35] and cellular lipids were extracted [36]. Briefly,
homogenised cell fractions were extracted, lipids separated
by thin-layer chromatography and radioactivity quantified by
liquid scintillation. Another non-polar solvent mixture of
hexane:ether:acetic acid (50:50:1) followed by hexane was
used to separate free cholesterol from diacylglycerol.
Total cholesterol Myotubes were harvested in 1 ml of
distilled H2O and the concentration of total cholesterol was
measured according to the suppliers protocol (bioMéreiux).
Cell-associated and oxidised palmitic acid Human myo-
tubes were grown and differentiated in 96-well CellBIND
tissue culture plates from Costar (Corning, NY, USA). Cells
were exposed for 4 h to Dulbecco’s phosphate-buffered
saline with 0.49 mmol/l Mg2+ and 0.90 mmol/l Ca2+
supplemented with [1-14C]palmitic acid (37 kBq/ml,
0.1 mmol/l), 10 mmol/l HEPES, 5 mmol/l glucose,
25 pmol/l insulin and 1 mmol/l L-carnitine and adjusted to
pH 7.2. Radioactive 14CO2 was trapped in a filter plate for
4 h before myotubes were placed on ice, washed twice with
PBS (150 μl/well) and 200 μl 0.05 mol/l NaOH added.
Lysed cell fractions (50 μl) and filter plates were quantified
by liquid scintillation (Wallac MicroBeta Trilux, Perkin-
Elmer, Oslo, Norway), as previously described [37]. Cells
were later assayed for protein.
Table 1 Clinical characteristics of the study participants
Participants
Lean Obese Obese type 2
diabetic
Age (years) 51±1 48±2 49±2
BMI (kg/m2) 24±1 37±2a 35±1a
Fasting plasma glucose
(mmol/l)
5.7±0.2 5.9±0.1 9.9±0.9b
Fasting serum insulin
(pmol/l)
24±7 37±7 92±10b
HbA1c (%) 5.6±0.1 5.5±0.1 7.9±0.6
b
Glucose infusion rate
(mg min−1 m−2)
406±21 224±28a 100±23b
Values are means±SEM (n=7).
a p<0.05 vs lean.
b p<0.05 vs lean and obese.
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RNA isolation and micro fluidic cards Myotubes were
washed and pelleted before total RNA was isolated by
RNeasy Mini kit according to the supplier protocol
(Qiagen). Samples were additionally incubated with RN-
ase-free DNase for a minimum of 15 min. Equal amounts of
RNA obtained from myotubes established from three
individuals from each donor group were pooled and
reverse-transcribed with the cDNA archive kit. Each sample
(100 ng cDNA) was added to the slot of a micro fluidic
card giving a total cDNA amount per well of about 2 ng.
The samples were run once on two separate micro fluidic
cards according to the suppliers protocol (Applied Bio-
systems). A micro fluidic card was designed to analyse 93
genes involved in lipid metabolism. GAPDH was used as
an internal control and a fold change of ≥2 was considered
an increase or a decrease in expression level.
Glucose uptake To study basal and insulin-mediated glucose
uptake, cultures were exposed for 4 h to DMEM supple-
mented with 0.24 mmol/l BSA, 2-deoxy-D-[3H]glucose
(7.4 kBq/well) and 25 pmol/l or 1 μmol/l insulin. Cells
were solubilised by addition of 500 μl 0.1 mol/l NaOH. An
aliquot (50 μl) was removed for protein determination [35]
and 300 μl was counted by liquid scintillation [38].
Glucose oxidation To study basal and insulin-mediated
glucose oxidation, cultures were incubated for 4 h with DMEM
supplemented with 0.24 mmol/l BSA, D-[1-14C]glucose
(74 kBq/ml, 5.5 mmol/l) and 25 pmol/l or 1 μmol/l insulin,
as previously described [33].
Analysis of gene expression by RT-PCR RNA was isolated
as described above. Total RNA (1 μg/μl) from seven lean
donors was reverse-transcribed with hexamer primers using
a thermal cycler (9600; Perkin-Elmer) (25°C for 10 min,
37°C for 1 h, 99°C for 5 min) and a TaqMan reverse-
transcription reagents kit. Real-time PCR was performed
using a detection system (ABI PRISM 7000; Applied
Biosystems, Oslo, Norway). DNA expression was deter-
mined by SYBR Green and primers, using PrimerExpress
(Applied Biosystems), as follows: 36B4 (Acc. no. M17885)
Forward: CCATTCTATCATCAACGGGTACAA, Reverse:
AGCAAGTGGGAAGGTGTAATCC); GAPDH (Acc. no.
J04038/M33197) Forward: TGCACCACCAACTGCT
TAGC, Reverse: GGCATGGACTGTGGTCATGAG);
GLUT1 (Acc. no. K03195) Forward: CAGCAGCCC
TAAGGATCTCTCA, Reverse: CCGGCTCGGCTGA
CATC); GLUT4 (Acc. no. M20747) Forward:
GCTACCTCTACATCATCCAGAATCTC, Reverse: CCA
GAAACATCGGCCCA); ChREBP (Acc. no. NM_032951)
Forward: CGGCATTGAGCTCCTCAATC, Reverse: GCA
GAAGACAGCTGAGTACATCCTTA. Each target gene
was quantified in triplicate, this being carried out in a
25 μl reaction volume according to the supplier’s protocol.
All assays were run for 40 cycles (95°C for 12 s followed
by 60°C for 60 s). The transcription levels were normalised
to the housekeeping control genes 36B4 and GAPDH.
Statistical analysis Data in text, tables and figures are given
as means (±SEM) and all cell culture experiments were run
in triplicate. Comparisons of different treatments and
between groups were evaluated by paired and unpaired
Student’s t tests, respectively. A value of p<0.05 was
considered significant.
Results
Cell cultures Myotubes showed no difference in morpho-
logical appearance after treatments with either T0901317,
T0901317+22-S-HC, 22-S-HC or 22-R-HC for 4 days.
Neither of the treatments reduced cellular protein levels
(data not shown) or leakage of lactate dehydrogenase (p>
0.4). Concentration of total cholesterol in myotubes was
unchanged by T0901317 and both 22-HCs after 4 days
(range 204±34 to 266±27 nmol/mg cell protein) (p>0.15).
Incorporation of radiolabelled acetate into fatty acids and
complex lipids Myotubes were treated either with
T0901317, T0901317+22-S-HC, 22-S-HC or 22-R-HC for
4 days before they were incubated with [1-14C]acetate for
4 h. The synthetic LXR agonist, T0901317, increased total
lipogenesis by two- to threefold (Fig. 1a). This effect was
more pronounced in myotubes from obese type 2 diabetic
patients than in cells from lean individuals (Fig. 1a), while
22-S-HC reduced lipogenesis 1.5- to 2.5-fold when com-
pared with baseline (DMSO 0.1%) and completely abol-
ished the effect of T0901317. Total lipogenesis was also
reduced by 22-R-HC in myotubes from lean and obese
individuals (Fig. 1a). In addition, T0901317 increased
incorporation of acetate into NEFA by three- to fivefold,
this increase being significantly higher in type 2 diabetic
cells than in myotubes from lean volunteers (Fig. 1b). The
synthetic LXR antagonist, 22-S-HC, reduced NEFA levels
in myotubes from lean volunteers by 30% when compared
with baseline and abolished almost completely the effect of
T0901317 (Fig. 1b). Diacylglycerol levels were increased
about twofold after treatment with T0901317 in cells from
obese and type 2 diabetic volunteers (Fig. 1c). A combi-
nation of T0901317 and 22-S-HC reduced diacylglycerol
levels by twofold compared with baseline, while 22-S-HC
reduced diacylglycerol levels by threefold (Fig. 1c). Cellu-
lar triacylglycerol levels were also increased by 3.5- to 5.5-
fold after exposure to T0901317, an effect that was
markedly reduced when T0901317 was combined with
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22-S-HC (Fig. 1d). Triacylglycerol levels were not altered
by treatment with 22-S-HC. However, after 22-S-HC
treatment triacylglycerol formation from acetate was sig-
nificantly higher in myotubes from obese and type 2
diabetic volunteers than in myotubes from lean volunteers
(Fig. 1d). Cholesteryl esters were increased by 50% after
treatment of myotubes from obese and type 2 diabetic
participants with T0901317; in myotubes from lean
participants only cholesteryl esters decreased after exposure
to 22-S-HC and 22-R-HC (Fig. 1e). Levels of free
cholesterol were 1.5- to 2.5-fold increased after exposure
to T0901317 and were significantly higher in type 2
diabetic cells than in myotubes from lean volunteers. After
exposure to oxysterols, free cholesterol was reduced two- to
eightfold, but significantly less in myotubes from type 2
diabetic than in those from lean volunteers (Fig. 1f).
Palmitic acid uptake and oxidation to carbon dioxide Cell-
associated palmitic acid was increased in all donor groups
after T0901317 treatment, but tended to increase more in
myotubes from obese and type 2 diabetic volunteers
(Fig. 2a). The T0901317-induced increase was 50% for
Fig. 1 Synthesis of cellular lipids from acetate after treatment with
LXR modulators. Differentiated myotubes were treated for 4 days
with 1 μmol/l T0901317 (T), 1 μmol/l T+10 μmol/l 22-S-HC (T+S-
HC), 10 μmol/l 22-S-HC or 10 μmol/l 22-R-HC (R-HC) and then
incubated with [1-14C]acetic acid (74 kBq/ml, 0.1 mmol/l) for 4 h. a
Total lipogenesis (range for baseline 0.4–1.4 nmol/mg cell protein; b
NEFA; c diacylglycerol (DAG); d triacylglycerol (TAG); e cholesteryl
ester (CE); and f free cholesterol (FC). Results are means±SEM (n=5–
7). ap<0.05 vs baseline, bp<0.05 vs all other treatments, cp<0.05 vs
lean myotubes, dp<0.05 vs 22-S-HC. Open bars, lean; hatched bars,
obese; closed bars, type 2 diabetes
Fig. 2 Cell-associated and oxidised palmitate after treatment with
LXR modulators. Human myotubes were grown and differentiated in
96-well CellBIND tissue culture plates, treated as described in Fig. 1
and then exposed for 4 h to [1-14C]palmitic acid (37 kBq/ml,
0.1 mmol/l) to measure cell-associated and oxidised palmitate. a
Range for baseline 38.0–86.5 nmol/mg cell protein; b range for
baseline 0.6–5.6 nmol/mg cell protein. CO2 was trapped on 96 well
filter plates for 4 h. Results are presented as means±SEM (n=5–6).
ap<0.05 vs baseline, bp<0.05 vs all other treatments, cp<0.05 vs
T0901317. Open bars, lean; hatched bars, obese; closed bars, type 2
diabetes
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lean and nearly twofold for obese and type 2 diabetic
myotubes, while the combination of 22-S-HC and
T0901317 significantly reduced the effect of T0901317
for lean and obese cells. In addition, cell-associated
palmitic acid was not influenced after treatment with 22-
S-HC or 22-R-HC (except for type 2 diabetic cells) and
there were no differences between cells from lean, obese
and type 2 diabetic participants (Fig. 2a). In obese
myotubes, palmitic acid oxidation to CO2 was increased
40% after T0901317 treatment and reduced ∼30% against
baseline, for lean and type 2 diabetic cells, by exposure to
22-S-HC. When compared with T0901317, T0901317+22-
S-HC reduced palmitic acid oxidation only in cells of type
2 diabetic origin (Fig. 2b).
Expression of genes involved in lipid formation and
cholesterol homeostasis Pooled RNA samples from myo-
tubes of lean, obese and type 2 diabetic individuals treated
with T0901317, T0901317+22-S-HC, 22-S-HC and 22-R-
HC were analysed on real-time micro fluidic cards. Since
there were no clear differences between the groups in gene
expression from pooled RNA, only data from lean
myotubes are presented. Expression of LXRα and SREBP-
1 was increased several times after chronic T0901317
treatment (Fig. 3a). The T0901317-induced elevation of
LXRα and SREBP-1 expression was reduced upon treat-
ment with T0901317+22-S-HC, while 22-S-HC alone did
not alter expression. Expression of LXRα and SREBP-1
were moderately increased by 22-R-HC (Fig. 3a). The
expression levels of genes directly involved in lipogenesis
and lipid formation, e.g. acetyl-coenzyme A carboxylase
(ACC1, also known as ACACA), FASN, stearoyl-coenzyme
A desaturase (SCD1) and acyl-coenzyme A synthetase long
chain family member 1 (ACSL1), were all increased by
T0901317 treatment (Fig. 3b). Interestingly, this effect was
abolished when T0901317 was combined with 22-S-HC
(Fig. 3b). The synthetic LXR ligand, 22-S-HC, reduced
expression levels of SCD1 and FASN (Fig. 3b) by sevenfold
below baseline, while 22-R-HC did not influence the
expression of any of these genes (Fig. 3b). None of the
treatments had effect on acetyl-coenzyme A carboxylase 2
(ACC2) expression (data not shown). Genes involved in
cholesterol homeostasis were also influenced by LXR-
ligands (Fig. 3c). Expression of the ATP-binding cassette
subfamily A1 (ABCA1) was increased 20-fold and 6-fold
after exposure to T0901317 and 22-R-HC, respectively.
Importantly, 22-S-HC alone or in combination with
T0901317 did not alter the expression of this gene
(Fig. 3c). In addition, expression of hydroxymethylglutaryl-
coenzyme A (HMGC) synthase 1 (HMGCS1) and HMGC
reductase (HMGCR) was not regulated by T0901317, but
decreased six- to sevenfold by 22-S-HC and by 2.5- to 3.5-
fold by 22-R-HC (Fig. 3c).
Glucose transport and oxidation T0901317 slightly in-
creased basal glucose transport as reported earlier. This
increase, however, was only significant when data from all
three donor-groups were pooled (data not shown). Treat-
ment with 22-S-HC increased glucose uptake by 30%, 40%
and 60% in myotubes from lean, obese and type 2 diabetic
individuals, respectively (Fig. 4a). Moreover, 22-S-HC
increased glucose transport equally in combination with
T0901317 (Fig. 4a). The insulin-stimulated glucose uptake
was in general unchanged after treatment with T0901317,
T0901317+22-S-HC, 22-S-HC or 22-R-HC in all groups
(Fig. 4b). To further evaluate intracellular glucose metab-
olism after chronic treatment with LXR ligands, glucose
oxidation assessed by CO2 trapping was studied. T0901317
increased basal glucose oxidation in myotubes from lean,
Fig. 3 Expression of genes involved in lipogenesis and cholesterol
homeostasis. Differentiated myotubes were treated with 1 μmol/l
T0901317 (closed bars), 1 μmol/l T0901317+10 μmol/l 22-S-HC
(dark hatched bars), 10 μmol/l 22-S-HC (light hatched bars) and
10 μmol/l 22-R-HC (checkered bars) for 4 days. Total RNA was
extracted, reverse-transcribed and analysed on micro fluidic cards. a
Expression of LXRα, SREBP-1 and the gene encoding uncoupling
protein 2 (UCP2). b Expression of genes involved in lipid
metabolism. c Expression of genes involved in cholesterol metabo-
lism. Results are normalised to levels of GAPDH, and a fold change
≥2 from baseline (open bars) was considered to be an increase or a
decrease in the level of expression (n=3 for each treatment, pooled
RNA)
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obese and type 2 diabetic individuals by 40%, 50% and
70%, respectively (Fig. 4c). All treatments with 22-S-HC
alone or in combination with T0901317, except for 22-S-
HC in lean myotubes, resulted in a significant increase (35–
90%) in glucose oxidation (Fig. 4c). The insulin-stimulated
glucose oxidation increased for T0901317 when compared
with baseline (Fig. 4d).
Expression of genes involved in glucose metabolism Myo-
tubes from lean volunteers were treated with T0901317,
T0901317+22-S-HC and 22-S-HC, before genes involved
in glucose metabolism were analysed by real-time PCR.
The expression levels of GLUT1 (Fig. 4e) were significant-
ly increased only after T0901317. GLUT4 was increased
fourfold after treatment with both T0901317 and T0901317
+22-S-HC, while 22-S-HC did not alter GLUT4 mRNA
expression (Fig. 4e). Importantly, ChREBP was increased
3.5-fold by T0901317, but this effect was completely
abolished when combined with 22-S-HC (Fig. 4e). Expo-
sure to 22-S-HC tended to reduce mRNA expression of
ChREBP (Fig. 4e).
Discussion
The present study shows that 22-S-HC, a possible LXR
antagonist, (1) repressed lipogenesis; (2) decreased forma-
tion of complex lipids and free cholesterol below baseline;
and (3) increased glucose transport and utilisation equally
in myotubes from lean, obese and type 2 diabetic
volunteers, without interfering with expression of the
ABCA1 transporter gene or concentration of total choles-
terol. Also, the synthetic LXR agonist T0901317 increased
both the expression of lipogenic genes and lipogenesis in
myotubes from lean, obese and type 2 diabetic individuals,
while 22-S-HC markedly suppressed these effects. Impor-
tantly, the T0901317-induced increase in lipogenesis was
more pronounced in myotubes from type 2 diabetic patients
than in cells from lean individuals.
Fig. 4 Glucose transport and oxidation in myotubes after chronic
treatment with LXR modulators. Differentiated myotubes were treated
as described in Fig. 1 and incubated with 2-deoxy-D-[3H]glucose or D-
[1-14C]glucose with or without 1 μmol/l insulin for 4 h or harvested
for total RNA extraction, reverse-transcribed and analysed by real-
time PCR. a Basal glucose transport; b insulin-stimulated minus basal
glucose transport; c basal glucose oxidation (CO2); d insulin-
stimulated minus basal glucose oxidation; and e GLUT1, GLUT4
and ChREBP mRNA levels. Results are normalised to levels of 36B4.
Means±SEM (n=6–7). ap<0.05 vs baseline (open bars), bp<0.05 vs
all other treatments.T2D, type 2 diabetes. Closed bars, T0901317;
dark hatched bars, T0901317+22-S-HC; light hatched bars, 22-S-HC;
checkered bars, 22-R-HC
R
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Activators of LXRs are potent stimulators of fatty acid
and triacylglycerol synthesis [1, 26]. This effect is mediated
to a large degree by LXR-dependent expression of SREBP-
1c and its downstream targets, FASN, ACC and SCD1 [18,
39]. Chisholm et al. [40] have demonstrated that adminis-
tration of T0901317 to male db/db mice for 12 days
resulted in a more severe hepatic triacylglycerol accumula-
tion than observed in non-diabetic mice. Recently, it has
been shown in human myotubes that LXR activation
promotes lipogenesis [30] and triacylglycerol accumulation
[29, 33]. These studies confirmed that activation of LXR
increases lipogenesis and lipid formation from acetate in
human myotubes and that myotubes established from type
2 diabetic individuals are more responsive than myotubes
from lean donors. In contrast, we have shown that 22-S-HC
reduced de novo lipogenesis in myotubes from all three
donor groups and efficiently counteracted the effects of
T0901317 on enhancing lipogenesis and lipid formation.
These functional isotope data correlated with the increased
expression levels of genes involved in lipogenesis after
treatment with T0901317 and with reduced expression after
exposure to 22-S-HC [30]. Several in vivo studies have
reported that insulin sensitivity can be restored after
depletion of accumulated lipids in rat skeletal muscle,
supporting a direct link between intramyocellular lipid
accumulation and insulin resistance [41, 42]. Previously, we
have shown in human myotubes from lean and type 2
diabetic volunteers that LXR activation by chronic agonist
treatment can increase uptake of fatty acids (palmitate) and
incorporation into diacylglycerol and triacylglycerol as well
as increasing fatty acid oxidation [33]. The present study
confirmed that LXR activation leads to an increased uptake
of fatty acids in myotubes from all three donor groups and
also showed that 22-S-HC can counteract these effects.
Therefore, the possibility of reducing accumulation of
intramyocellular lipids by an LXR antagonist could have
a great therapeutic potential, although the mechanism
linking intramyocellular lipid to insulin resistance is still
not fully elucidated [43].
Effects of LXR ligands on cholesterol turnover in cells
have not been comprehensively examined. Aravindhan et al.
[44] recently showed in HepG2 cells that cellular choles-
terol fluxes were altered by LXR activation and that the
increase in cholesterol synthesis did not compensate for the
increased cellular cholesterol efflux, resulting in a net
cellular cholesterol loss. We have previously demonstrated
that LXR activation increased levels of cholesterol esters
from labelled palmitic acid in human myotubes [33]. The
present study shows that levels of free cholesterol and
cholesterol esters from labelled acetate and palmitic acid
increased after T0901317 treatment, but were markedly
reduced by both 22-HC isoforms. Furthermore, Peet et al.
[45] have reported that LXRα−/− knockout mice have
impaired expression of HMGCS and HMGCR and that
expression and degradation of both are controlled by sterols
through their sterol sensing domain and SREBP2 (reviewed
in [46]). We observed decreased mRNA levels of HMGCS
and HMGCR after exposure to both 22-HC isomers.
Interestingly, unlike 22-R-HC, 22-S-HC decreased expres-
sion of HMGCS and HMGCR without altering the
expression of ABCA1. In contrast to observations in genes
involved in lipogenesis, 22-S-HC was unable to counteract
the T0901317-induced expression of ABCA1 and GLUT4.
This suggests that LXR-dependent regulation of lipogenesis
versus reverse cholesterol and glucose transport may
involve different regulatory pathways.
Surprisingly, 22-S-HC seemed to increase basal glucose
transport and glucose oxidation. This could not be
explained by increased expression of glucose transporters
since expression of GLUT1 and GLUT4 was unaltered by
22-S-HC. In line with previous observations [33], the
expression of glucose transporters was induced by
T0901317, but resulted in a marginal increase in glucose
uptake. Thus, the mechanisms by which 22-S-HC elevates
basal glucose transport is at present unknown. However,
increased glucose uptake and oxidation can be secondary
effects to reduced lipogenesis and lipid handling, resulting
in an increased capacity of mitochondria to oxidise glucose
and possibly demand a higher glucose uptake [47]. In line
with this, Shigematsu et al. [48] have shown that depletion
of plasma membrane cholesterol resulted in an insulin-
independent increase in membrane-localised GLUT4,
which was reversible by cholesterol replenishment. We
observed that 22-S-HC reduced synthesis of free cholesterol
in myotubes and increased transport of glucose suggesting a
possible connection. However, concentrations of total cell
cholesterol were unchanged and 22-R-HC also reduced
synthesis of free cholesterol without increasing glucose
transport. In addition, two research groups have recently
demonstrated in ob/ob mice deficient in ChREBP or with
liver-specific inhibition of this protein that these animals
have reduced plasma glucose concentrations without a
reduction in plasma insulin levels as well as reduced
lipogenesis due to a decrease in Scd1 and Acc1 mRNA
levels and activity [49, 50]. In line with this, we observed
that exposure to 22-S-HC abolished T0901317-induced
expression of ChREBP, reduced basal mRNA levels,
increased basal glucose transport and reduced lipogenesis.
This implies that the observed effects of 22-S-HC on
glucose transport and lipogenesis in human skeletal muscle
could be mediated through reduced expression of ChREBP.
In summary, this study shows that treatment with an
LXR agonist (T0901317) increased lipogenesis and lipid
formation more extensively in myotubes from type 2
diabetic patients than in myotubes from lean individuals.
Further, 22-S-HC counteracted the effects of T0901317 on
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lipid metabolism and reduced de novo lipogenesis below
baseline, while at the same time glucose uptake and
oxidation were increased. Importantly, 22-S-HC also
decreased the expression of genes involved in cholesterol
synthesis without altering the expression of the reverse
cholesterol transporter ABCA1. On the basis of the observed
metabolic effects on myotubes in vitro, an LXR antagonist
could have therapeutic potential in the treatment of obesity
and type 2 diabetes. However, further research is required
to establish whether 22-S-HC itself or derivatives might
have similar effects in vivo.
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